This slideshow reviews osimertinib (Tagrisso), indicated for HFirst-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations.
Table of Contents
Slide 4: Dosage and Administration Slide 14: Cautions, Effects, and Interactions Slide 22: What to Tell Your Patient Slide 29: Reference
